MBHB Partner Kevin Noonan Authors BioPharm Article Entitled, “Biosimilar Names Prove Difficult to Define”

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Biosimilar Names Prove Difficult to Define” that appears in the March 1, 2017 online edition of BioPharmInternational.com. A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts. view the article